Health Canada approves Novartis' KISQALI® for HR+/HER2- early breast cancer patients at high risk of recurrence Français
Despite endocrine therapy (ET), the risk of recurrence for people diagnosed with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) early breast cancer (eBC) remains high, in addition to the possibility of an incurable metastatic relapse. 1
Health Canada approval is based on the pivotal Phase III NATALEE trial data, which demonstrated a clinically meaningful invasive disease-free survival (iDFS) benefit for KISQALI ® plus adjuvant aromatase inhibitor (AI) in patients with stage II or III HR+/HER2- eBC. 2
KISQALI is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival in three Phase III trials in advanced breast cancer. 3,4,5
MONTREAL, June 18, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI ® (ribociclib tablets) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adult patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) stage II-III early breast cancer (eBC) at high risk of recurrence. 2
Breast cancer is one of the most common cancers globally, 6 with HR+/HER2- being the most prevalent subtype, accounting for approximately 70% of cases. 7,8,9 Over 40% of HR+/HER2- breast cancer cases are diagnosed at stage II or III, with a high risk of recurrence for up to 20 years.8, 9 If cancer recurs, it is often metastatic which in most cases is considered incurable. 10,11 This progression significantly increases the burden on patients, caregivers, and healthcare systems, both financially and emotionally. 11,12 On average, 15 Canadian women will die from breast cancer every day. 13
"Over our years supporting younger patients, we've seen far too many with HR+ breast cancer become metastatic even while on maintenance endocrine therapy," said MJ DeCoteau, Founder and Executive Director, Rethink Breast Cancer. "Breast cancer is often more aggressive in younger patients, and they have higher rates of recurrence despite early treatment. So, we were thrilled to see that the positive results for KISQALI for early breast cancer are the same for patients of all ages, regardless of stage and nodal status. Our community desperately wants more effective tools to help improve their chances against this challenging disease that's turned their life plans upside-down. This Health Canada approval is an exciting step forward."
The Health Canada approval is based on the global Phase III NATALEE trial, which included a broad patient population with HR+/HER2- stage II and III eBC. At the final analysis, this clinical trial demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence with ribociclib plus AI compared to AI alone. Among patients with stage II and stage III eBC, ribociclib added to AI demonstrated a 25.1% relative reduction in the risk of an invasive disease-free survival (iDFS) event compared with AI alone, 1 with a well-tolerated safety profile seen across all subgroups in pivotal Phase III NATALEE trial. 2,4,14,15
"In the NATALEE trial, ribociclib demonstrated significant efficacy for a broad population of patients with early breast cancer," 2 said Dr. Stephen Chia, Medical Oncologist, BC Cancer and Steering Committee member of the NATALEE trial. "This approval provides a new and expanded treatment option for these patients to help reduce their risk of cancer returning. Patients deserve access to the most effective treatment options, and their individual needs should always be at the centre of shared decision making. In every situation, it's critical to have an open, balanced risk-benefit discussion, in order to make the appropriate treatment decision that's best suited for the patient to reduce the risk of their cancer returning."
"While the risk of cancer returning peaks in the first five years after diagnosis, more than half of recurrences occur after this period, and the majority are metastatic and incurable," 16,17 said Dr. Katarzyna Jerzak, Medical Oncologist, Sunnybrook Health Sciences Centre. "Ribociclib provides a new treatment option to help reduce the risk of recurrence and improve outcomes, particularly for patients at elevated risk. This approval expands our treatment arsenal with a targeted therapy that will have a meaningful impact on improving the care of patients diagnosed with early breast cancer in Canada."
"Novartis has been advancing innovative research and medical practice in breast cancer care for over 35 years, developing one of the most comprehensive pipelines in the field. Over 100,000 people with HR+/HER2- metastatic breast cancer have been treated with KISQALI globally, 18 and now we're focused on expanding its use to those with stage II or III HR+/HER2- early breast cancer to reduce risk of recurrence," said Mark Vineis, Country President, Novartis Canada. "We are actively committed to working with our health system partners to ensure timely access to KISQALI and supporting Canadians and healthcare professionals to improve health outcomes."
About early breast cancer (eBC)
Breast cancer is the most commonly diagnosed cancer among Canadian women, with approximately 70% of cases diagnosed in the early stages of the disease. 7,8,11 However, despite existing treatment options, people with stage II and III HR+/HER2- eBC remain at significant risk of recurrence. 11,12
The risk of recurrence is influenced by factors such as lymph node involvement, tumor size, age at diagnosis, and biomarkers. While patients without lymph node involvement typically have a lower risk, nearly 25% of those with HR+/HER2- eBC may experience recurrence within 20 years, 1 peaking after the first five years. 19 However, more than half of recurrences still happen after five years and more than 80% of these cases are metastatic and incurable. 20
About KISQALI ® (ribociclib tablets)
KISQALI was previously approved by Health Canada on March 2, 2018, for the treatment of patients with HR+/HER2- advanced or metastatic breast cancer. 20
KISQALI is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. 2
In eBC, KISQALI is the only CDK4/6 inhibitor recommended for both all node-positive disease and patients with no nodal involvement with high-risk disease characteristics. 20,21 The National Comprehensive Cancer Network (NCCN) guidelines recommend ribociclib (KISQALI) as a Category 1 preferred CDK4/6 inhibitor for breast cancer patients. 21 KISQALI, in combination with an AI, has the highest score (A) on the ESMO-Magnitude of Clinical Benefit Scale for the adjuvant treatment of adults with stage II and III HR+/HER2- eBC, at high risk of recurrence. 22
The most common Adverse Drug Reactions across the NATALEE study (>20% and exceeding the frequency for AI alone) were neutropenia (62.5% vs. 4.6%), infections (36.3% vs. 26.3%), nausea (23.3% vs.7.8%, headache (23.0% vs. 17.1%), fatigue (22.3% vs. 13.2%), leukopenia (22.3% vs. 3.6%), and abnormal liver function tests (22.3% vs. 7.6%). 2
Please see the Product Monograph for KISQALI, available at https://www.novartis.com/ca-en/kisqalimonograph.
About NATALEE
NATALEE is a global Phase III multi-centre, randomized, open-label trial to evaluate the efficacy and safety of KISQALI with an AI as an investigational adjuvant treatment versus AI alone in patients with stage II and III HR+/HER2- eBC. The adjuvant ET in both treatment arms was a non-steroidal aromatase inhibitor (NSAI; anastrozole or letrozole) and goserelin, if applicable. The primary endpoint of NATALEE was invasive disease-free survival (iDFS) as defined by the Standardized Definitions for Efficacy End Points (STEEP) criteria. A total of 5,101 adult patients with HR+/HER2- eBC across 20 countries were randomized in the trial. 13,23
About Novartis
Novartis is a focused innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
In Canada, Novartis Pharmaceuticals Canada Inc. employs approximately 600 people to serve the evolving needs of patients and the healthcare system and invests over $30 million in R&D yearly in the country. For more information visit www.novartis.ca.
SOURCE Novartis Pharmaceuticals Canada Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
10 hours ago
- Toronto Star
Sweaty feet, shaving rash: Sticky-summer advice from Toronto's viral hygiene expert Madame Sweat
'I tell people armpits are like rainforests — moist, dark and full of bacteria,' says Mary Futher, more famously known as Madame Sweat. If you aren't already following her, you're missing out. Madame Sweat is the internet authority on hygiene and personal care etiquette, gross grooming truths and tricks for keeping your body and home germ-free, with 1.1 million followers on Instagram and 18.3 million likes on her TikTok posts. And she happens to be Canadian.
Canada Standard
11 hours ago
- Canada Standard
World Refugee Day: Prolonged refugee separation is harming families - and Canada's economy
As World Refugee Day approaches on June 20, advocates and health experts are calling on the Canadian government to urgently address prolonged family separation for refugees. With wait times for family reunification now averaging more than four years, critics say the delays are causing irreparable harm to refugee families and imposing long-term costs on the health-care system and the Canadian economy. The significant health, social and economic costs of prolonged family separation merit urgent action. These costs are borne by refugees and their families as well as municipal, provincial and federal governments. People seeking refugee protection whose claims are accepted in Canada receive protected person status and are allowed to apply for permanent residence. They are permitted to include dependent children and spouses who are outside Canada on their permanent residence applications. While accepted refugees and their family members are legally eligible for permanent residence in Canada, they must be admitted under the immigration levels for Protected Persons in Canada and Dependants Abroad. Because the number of people applying under these levels exceeds the number of spaces available, family separation currently lasts 50 months. In 2024, the government of Canada announced major reductions in immigration levels starting in 2025. These reductions will further delay family reunification, prolonging refugees' bureaucratic limbo. Studies document the several mental health consequences of the separation of children from their parent(s), and of spouses from their partner. These challenges intensify as the duration of the separation increases. Medical associations around the world say family separation is a traumatic event that can cause developmental regression and higher rates of unexplained illness in children. This trauma may stem from the sense of abandonment that children experience while being separated from their parents. In one study from 2005, an interviewee said: "It was hard at first ... .The children thought that I had abandoned them. They considered me a traitor." Despite the time and efforts invested in long-distance relationships, family breakdown may result from prolonged family separation, necessitating counselling or child protection services. These mental health consequences not only have human costs. They also represent a financial burden for the Canadian government through the Interim Federal Health Care (IFHC) Program. After protected people transition away from IFHC, provincial and territorial governments pay for health costs associated with family separation. Some children may also require school-based interventions, mental health services and counselling, the costs of which are also borne by provincial governments. Protected people separated from their families also pay to maintain two households: one in Canada and one overseas. In a 2019 study, a refugee said that "sending remittances was more expensive than if they lived together in Canada." Remittances not only represent a financial challenge to refugee families, they also result in indirect economic losses to Canada as funds leave the country instead of being invested in Canada. Research shows that family separation also inhibits integration. The inability to find affordable child care in a single-parent household, for example, limits the ability to learn official languages, participate in community groups and find work opportunities. For example, one woman from Afghanistan who had been waiting more than six years for reunification with her husband told researchers: "In night I sometimes cannot sleep and I just walk and walk around the lobby of my apartment building. [...] I can no longer take care of my children when they're missing all the time their father. They need their father. Even sometimes my family asking 'where is he?' and other kids at my children's schools are asking." This stress caused severe mental and physical health issues for this woman and her family, further limiting her ability to work. These integration challenges mean fewer people can work to their full capacity, limiting participation in the Canadian economy. Delayed economic integration due to family separation results in lower tax revenues for all levels of the Canadian government. Family unity provides refugees with the necessary support to manage the stresses of resettlement. Family reunification increases flexibility to adjust to a new country and culture without additional challenges. As refugees and their families integrate, Canada benefits. They find work, pay taxes and contribute to their communities. The United Nations declared June 20 to be World Refugee Day almost 25 years ago. Although it's just one day, it reminds us to honour refugees from around the world. It is a good time for the Canadian government to work towards issuing temporary visas to eligible family members, allowing them to live in Canada while they await permanent residence. The right to family unity is protected by international law. Canada's reputation as a leader in refugee protection is at risk if family reunification continues to be delayed. The social, health and economic costs of family separation are both inhumane and unnecessary.
Toronto Star
11 hours ago
- Toronto Star
Sweaty feet, shaving rash and soggy swimwear: Sticky-summer advice from Toronto's viral hygiene expert Madame Sweat
'I tell people armpits are like rainforests — moist, dark and full of bacteria,' says Mary Futher, more famously known as Madame Sweat. If you aren't already following her, you're missing out. Madame Sweat is the internet authority on hygiene and personal care etiquette, gross grooming truths and tricks for keeping your body and home germ-free, with 1.1 million followers on Instagram and 18.3 million likes on her TikTok posts. And she happens to be Canadian.
